European Institute of Oncology
Milan, Italy
Location contact
Francesco Ceci
CONTACT
NCT Number: NCT06474975
This study is a diagnostic open-label, prospective, single-arm non-inferiority clinical trial.
The primary endpoint is the accuracy to detect positive invasive margins in invasive ductal carcinoma (IDC) patients by high-resolution specimen Positron Emission Tomography/Computed Tomography (PET/CT) imaging.
Trial opening soon.
Get Notified18 year and older
Female
Interventional
Not applicable
Milan, Italy
Francesco Ceci
CONTACT
The rationale of this study is to examine the non-inferiority of intraoperative high-resolution specimen PET/CT imaging in early-stage breast cancer for the identification of all positive margins of the invasive component during Breast Cancer Surgery (BCS) as compared to standard-of-care gross pathology evaluation.
The PET/CT specimen imager is used to intraoperatively assess resection margins and histopathological findings of the breast tumor specimen are applied as the gold standard.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The PET/CT specimen imager (AURA 10 PET/CT) is used to intraoperatively assess resection margins and histopathological findings of the breast tumor specimen are applied as the gold standard
Other names: PET/CT specimen imager (AURA 10 PET/CT)
Time frame: 1 month
Evaluation of intraoperative high-resolution specimen PET/CT imaging for the identification of all invasive positive margins during primary breast-conserving surgery (BCS) of invasive ductal carcinoma (IDC), as compared to perioperative gross pathology evaluation. Permanent pathology is used as the gold standard for margin assessment.
Time frame: 1 month
determining the diagnostic performance of intraoperative high-resolution specimen PET/CT imaging and gross pathology to detect all positive margin;
Time frame: 1 month
exploring the ability of intraoperative high-resolution specimen PET/CT imaging to detect the presence of malignant cells in resected lymph nodes and cavity shaves;
Time frame: 1 months
determining the optimal SUVmax cut-off in intraoperative high-resolution specimen PET/CT imaging for the correct detection of malignant vs. non-malignant tissues, using pathology results as standard-of-reference
Contact information is provided by the study sponsor or research team.
Francesco Ceci, MD
CONTACT
Francesco Mattana
CONTACT
European Institute of Oncology
Other
SURGYPET: Intra-SURGerY High-resolution Specimen PET/CT Imager for Margin Assessment in Early-stage Breast Cancer as Compared to Gross Pathology: a Prospective Non-inferiority Analysis
Acronym: SURGYPET
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07185568
Breast Cancer, Breast Diseases
Roma, RM, Italy
View Trial DetailsNCT07206121
Breast Cancer, Breast Cancer - Infiltrating Ductal Carcinoma
Galveston, Texas, United States
View Trial DetailsNCT06120439
Breast Cancer, Breast Diseases
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT05838001
Breast Cancer, Breast Diseases
Guangzhou, Guangdong, China
View Trial Details